About Michael Silber

This author has not yet filled in any details.
So far Michael Silber has created 2157 blog entries.

Illinois

Sent a notice to inform providers that, due to the continued prevalence of Respiratory Syncytial Virus (RSV), the Department of Healthcare and Family Services (HFS) is extending its coverage for Synagis (palivizumab) through March 31, 2024. This applies to customers covered under Medicaid fee-for-service (FFS) or a managed care plan. Providers should contact the appropriate managed care plan for approval guidance.  

Due to the security breach and subsequent system outage at Change Healthcare, HFS’ Pharmacy Benefits Management System (PBMS) for the FFS program, providers are unable to obtain prior approval. Providers billing on the 837 Professional claim format may submit their claims for Synagis without prior approval. Pharmacies are encouraged, in good faith, to continue to provide this medication as needed. Once the system is operational, HFS will make pharmacies whole and assist with claim submissions and provide any necessary overrides.  

Questions regarding this notice may be directed to a pharmacy consultant in the Bureau of Professional and Ancillary Services at 877-782-5565, or the appropriate managed care plan 

Also in Illinois, HFS would like to thank our pharmacy partners who have been working tirelessly to ensure Medicaid customers receive their necessary medications. During this system outage, medications, including medications that normally require prior authorization, will not be subject to a post approval process. HFS will pay all clean claims submitted once the PBMS system is operational. Prescriptions filled in good faith will be paid in full as soon as the issue is resolved. HFS cannot provide an estimate on when the system issue will be resolved. 

We want to reiterate that pharmacies should continue to check eligibility, which they can do by checking one of the following resources: 

  • MEDI – www.myhfs.illinois.gov  
  • AVRS – 800-846-1461 
  • Recipient Eligibility Verification (REV) System 
  • During business hours, calling 800-252-8942 or 877-782-5565 Option 7 

Additionally, pharmacists should take particular care to consult with their patients regarding their current medications, and health and medication history to reduce the risk of adverse events.   

Questions regarding this notice may be directed to a pharmacy consultant in the Bureau of Professional and Ancillary Services at 877-782-5565. 

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2024-03-08T11:34:04-05:00March 8, 2024|Illinois|

Idaho

HB 527 passed the House and was assigned to the Senate Health & Welfare Committee where it was reported out of committee with “Do Pass Recommendation.” If enacted, this bill puts into statute the current practices of pharmacy that were either part of rule or standard procedures, but not codified. This will give stability to the changes that have helped to expand access to pharmacy services in the state

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2024-03-08T11:33:14-05:00March 8, 2024|Idaho|

Louisiana

A HIVPEP/PrEP bill, HB 579, was pre-filed by State Rep. Wayne McMahan (R). The bill is modeled after the 2023 Arkansas law (Act 314). 

Also in Louisiana, the Department of Health (LDH) issued an Informational Bulletin 24-3:  updating the immunization fee schedule. 

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2024-03-08T11:32:36-05:00March 8, 2024|Louisiana|

Maryland

The Maryland House and Government Operations Committee Subcommittee on Insurance and Pharmaceuticals met this week and advanced an amended version of HB 76, a bill that would expand pharmacists’ ability to immunize children. The negotiated amendment to the bill would allow pharmacies to provide COVID, flu and any vaccine available because of a public health emergency to children aged 3 and older, as well as all ACIP-recommended vaccines and travel vaccines to children 7 years of age and older. The bill was reported out of subcommittee with 3 negative votes. It now goes to the full House. 

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2024-03-08T11:31:54-05:00March 8, 2024|Maryland|

New York

On March 5th, the NYRx Clinical Call Center reported that they are experiencing higher than normal call and fax volume. Prescribers should not send duplicate prior authorization (PA) requests to NYRx. Prescribers may experience a higher volume of requests for PA, but only one submission is necessary. Pharmacies should only request one PA for each member for each drug. Duplicate requests slow down the processing time at the NYRx Clinical Call Center. For more information, refer to NYRx Notice to Providers: Duplicate Prior Authorization Requests. To review how to submit a PA to NYRx, refer to the NYRx Prior Authorization Submission Guide. 

Enhancements have been made to the NYRx clinical criteria system editing. The clinical criteria have not changed and should be reviewed on the NYRx Preferred Drug List prior to obtaining a PA. Preferred products should be prescribed when clinically appropriate. In most cases, preferred products will not require a PA when prescribed according to FDA (FOOD AND DRUG ADMINISTRATION) labeling. To review NYRx preferred products only, refer to the NYRx Preferred Drug Quick List. 

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

2024-03-08T11:30:52-05:00March 8, 2024|New York|

Missouri

The House Health & Mental Health Committee held a hearing Monday on PBM reform legislation, HB 1627 by Rep. Dale Wright. More than 40 pharmacists showed up at the Capitol to voice their support. The theme of the day was “Enough is enough” with PBM abuses. Go to the Missouri Pharmacy Association’s (MPA) website for more information.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2024-03-08T11:30:17-05:00March 8, 2024|Missouri|

Oregon

On March 4, the Board of Pharmacy issued this temporary rule notice: 

This revised protocol permits pharmacists to provide an additional updated 2023-2024 COVID-19 vaccine dose to adults ages 65 years and older in alignment with the recent recommendation of the CDC (Centers for Disease Control) Advisory Committee on Immunization Practices’ (ACIP). 

Also on Oregon, the Board of Pharmacy issued the following temporary rule notice:  

Also in Oregon, the Board of Pharmacy permanently repealed the following rules at the Special February 23, 2024, Board Meeting: OAR 855-019-0270, OAR 855-019-0280, OAR 855-019-0290 and OAR 855-025-0024 related to Pharmacist/COPT/PT Administration of Vaccines (Effective February 29, 2024)  

Also in Oregon, the Board of Pharmacy permanently adopted the following rule at the February 2024 Board Meeting: OAR 855-115-0150 Pharmacist- Prohibited Practices (Effective March 1, 2024). Please note this rulemaking removes “Diagnosis” from the list of prohibited practices. 

Finally in Oregon, the Prescription Drug Affordability Board posted the draft agenda for its next meeting on March 20. Please register in advance of the meeting.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2024-03-08T11:29:18-05:00March 8, 2024|Oregon|

Pennsylvania

The Board of Pharmacy’sproposed pharmacy technician registration regs were published on March 2 and are now before the Independent Regulatory Review Commission and the designated standing committees of the PA House and Senate for consideration. Comments are due to IRRC by April 1; after reviewing IRRC will provide any comments back to the BOP (Board of Pharmacy) by May 1. Members may submit comments to Jill McCormack by March 20.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2024-03-08T11:26:21-05:00March 8, 2024|Pennsylvania|
Go to Top